Biohaven Ltd. (BHVN)

In August 2025, Biohaven reported its second-quarter financial results, announced positive data from its MoDE degrader BHV-1300 and TRAP degrader BHV-1400 programs, and commenced enrollment for a pivotal Phase 2/3 study of BHV-8000 in Parkinson's disease. In September 2025, a securities class action lawsuit was filed against Biohaven. In November 2025, the FDA issued a Complete Response Letter for VYGLXIA and BHV-7000 failed to meet its primary endpoint in a mid-stage study for major depressive disorder, leading to restructuring and R&D expense cuts. In December 2025, Biohaven reported positive Phase 1 degrader data for BHV-1300. In January 2026, the company saw various analyst rating updates. In February 2026, Goldman Sachs initiated coverage on Biohaven Pharma stock with a Buy rating.

Biohaven Ltd. does not currently have marketed products that would typically experience traditional demand seasonality, as the company's revenue generation is primarily tied to its drug development milestones, partnerships, and potential future commercialization of its pipeline products.

Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurological, neuropsychiatric, immunological, and oncological diseases. Its pipeline includes VYGLXIA (troriluzole), MoDE and TRAP degrader platforms, oncology programs like BHV-1510 and BHV-1530, BHV-7000, taldefgrobep alfa, and BHV-8000.

Biohaven Ltd. is a global clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, with a primary focus on discovering and developing therapies in the United States.

Biohaven's brand reputation has been impacted by the FDA's rejection of VYGLXIA, the failure of BHV-7000 in a major depressive disorder study, and a securities class action lawsuit. Positive data from degrader programs and some analyst upgrades offer a mixed view of the company's standing.

Biohaven Ltd. has a substantial institutional ownership base, with 462 institutional owners and shareholders holding a total of 99,472,428 shares, accounting for 67.13% of the total shares outstanding, while insiders own 7.51% of the stock. Major institutional owners include BlackRock, Inc., Janus Henderson Group Plc, Stifel Financial Corp, Suvretta Capital Management, Llc, Vanguard Group Inc, State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Bellevue Group AG, Fmr Llc, and IWM - iShares Russell 2000 ETF.